| 23rd week of 2013 patent applcation highlights part 46 |
| Patent application number | Title | Published |
|---|
| 20130143795 | METHOD OF TREATMENT OF HIV OR AIDS - The invention relates to a method of treating HIV or AIDS comprising administering a composition comprising a polypeptide comprising LKKTETQ (SEQ ID NO: 1) or a variant thereof, or administering a composition comprising a peptidomimetic of a polypeptide comprising amino acid sequence LKKTETQ (SEQ ID NO: 1) or a variant thereof. | 2013-06-06 |
| 20130143796 | CHIMERIC POLYPEPTIDES AND USES THEREOF - The disclosure provides nucleic acid molecules encoding chimeric polypeptides, chimeric polypeptides, pharmaceutical compositions comprising chimeric polypeptides, and methods for treating metabolic disorders such as diabetes and obesity using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2013-06-06 |
| 20130143797 | Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof - The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α | 2013-06-06 |
| 20130143798 | NOVEL GLUCAGON ANALOGUES - The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 2013-06-06 |
| 20130143799 | NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS - Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. | 2013-06-06 |
| 20130143800 | COMBINATION THERAPIES TO TREAT DIABETES - Provided are methods for treating diabetes comprising administering to a patient a GLP-1 agonist and an iron chelator. In various embodiments, methods are provided for culturing pancreatic beta islet cells comprising contacting the beta cells with a GLP-1 agonist and an iron chelator in an amount effective to promote survival of the beta cells. | 2013-06-06 |
| 20130143801 | METHODS AND COMPOSITIONS FOR DELIVERING PEPTIDES - Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery. | 2013-06-06 |
| 20130143802 | FUSION PEPTIDE THERAPEUTIC COMPOSITIONS - Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life. etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs. | 2013-06-06 |
| 20130143803 | Process for the Preparation of Insulin-Zinc Complexes - The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation. | 2013-06-06 |
| 20130143804 | Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus - Methods for predicting a propensity for heart or kidney failure in a diabetic or pre-diabetic individual by determining the amount and/or molecular weight of islet amyloid polypeptide present in a sample from the individual are provided. | 2013-06-06 |
| 20130143805 | GGF2 AND METHODS OF USE - Provided herein are methods of treating central nervous system injury (e.g., spinal cord injury) using GGF2 and compositions comprising GGF2. For example, provided is a method of treating spinal cord injury in a subject, comprising administering at least one dosage of less than 1 mg/kg of GGF2 to the subject. Also provided are methods of promoting proliferation of neural stem cells and of promoting revascularization comprising using GGF2 and compositions comprising GGF2. | 2013-06-06 |
| 20130143806 | METHOD FOR EARLY PROGNOSIS OF KIDNEY DISEASE - Certain embodiments of the present invention relate to methods for detecting kidney disease, in particular early stage kidney disease. | 2013-06-06 |
| 20130143807 | Concentrated Protein Preparations of Bone Morphogenetic Proteins and Methods of Use Thereof - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 2013-06-06 |
| 20130143808 | Fibrin Gel for Controlled Release of PDGF and Uses Thereof - The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases. | 2013-06-06 |
| 20130143809 | NEUROTROPHIC PEPTIDES - The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1) and alternatively comprising an adamantyl group at the C- and/or N-terminal end. The neurotrophic peptide can rescue cognition, correct impairments in neural cell proliferation and synaptic plasticity, and thus address the cognitive defects associated with Down syndrome. | 2013-06-06 |
| 20130143810 | Virally-Inactivated Growth Factors-Containing Platelet Lysate Depleted of PDGF and VEGF and Preparation Method Thereof - The invention concerns human platelet extracts rich in growth factors (PGF) for wound healing and stem cell expansion. Accordingly the subject invention relates to a virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining a platelet lysate comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating the starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase, and incubating the solvent and/or detergent-treated platelet concentrate or the aqueous protein phase with charcoal. | 2013-06-06 |
| 20130143811 | Tumor Suppression Compositions - Provided herein is tumor suppression composition and methods of making and using the same. | 2013-06-06 |
| 20130143812 | ANTI-INFLAMMATORY DRUG - Provided is a new anti-inflammatory drug that produces an anti-inflammatory effect by modulating macrophage function. Specifically, a new anti-inflammatory drug that produces an anti-inflammatory effect through induction of M2 macrophages using activin species is provided. | 2013-06-06 |
| 20130143813 | METHODS AND COMPOSITIONS FOR MODULATING HGF/MET - The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met. | 2013-06-06 |
| 20130143814 | Protein Therapy for Treatment of Eye Diseases - The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. | 2013-06-06 |
| 20130143815 | GROWTH HORMONE CONJUGATES - The present invention relates to growth hormone conjugates comprising a bile acid residue, said conjugation may occur through wt or mutant amino acid residues. The growth hormone polypeptide may be wt human growth hormone or a growth hormone variant. | 2013-06-06 |
| 20130143816 | ISOFORMS OF BRAIN NATRIURETIC PEPTIDE - Methods and materials for diagnosing and treating heart conditions (e.g., heart failure) and kidney conditions (e.g., kidney failure) are described. | 2013-06-06 |
| 20130143817 | USE OF TRANSFERRIN IN TREATMENT OF BETA-THALASSEMIAS - Disclosed herein are methods for treating disease, such as diseases of iron overload, including β-thalassemia, comprising administering at least one course of transferrin and thereby reducing the size of the spleen in said patient and reducing the concentration of iron in the tissues and blood. | 2013-06-06 |
| 20130143818 | Factor VIII Glycoforms - The invention concerns glycosylated proteins having human factor VIII activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting GlcNAc linked to a core beta-mannose. | 2013-06-06 |
| 20130143819 | FERRIMANNITOL-OVALBUMIN TABLET COMPOSITION - The invention refers to an oral pharmaceutical tableted dosage form which comprises a mixture of: a) granules comprising ferrimannitol-ovalbumin (FMOA) and at least an intragranular pharmaceutical acceptable excipient including a binder; and b) extragranular pharmaceutical excipients including a filler and a binder; which may be obtained by wet-granulation and compression. | 2013-06-06 |
| 20130143820 | DIURETIC AND NATRIURETIC POLYPEPTIDES - This document provides diuretic and natriuretic polypeptides. For example, this document provides polypeptides having diuretic and/or natriuretic activities. In some cases, a polypeptide provided herein can have diuretic and natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing diuretic and/or natriuretic activities within a mammal. | 2013-06-06 |
| 20130143821 | HYDROPHOBICALLY-MODIFIED HYALURONAN AND METHODS OF MAKING AND USING THEREOF - Described herein are modified hyaluronans or the pharmaceutically-acceptable salt or ester thereof, wherein the modified hyaluronan comprises at least one hydrophobic polypeptide covalently bonded to hyaluronan. The modified hyaluronans can be used as viscosupplements in a number of medical applications. The modified hyaluronans can also be used in several biological and medical applications. Methods for preparing the modified hyaluronans are also provided herein. | 2013-06-06 |
| 20130143822 | AGENTS FOR TREATING ALZHEIMER'S DISEASE - Agents for treating Alzheimer's disease comprising a peptide according to sequence no. 1 which binds to Aβ oligomers and thus results in the healing or alleviation of Alzheimer's disease. In further embodiments peptides are provided which contain a sequence no. 1, but have preceding sequence sections which allow the peptide to be secreted. For the purpose of gene therapy, corresponding DNA sequences and vectors, in particular according to sequences 3 to 6, are provided. | 2013-06-06 |
| 20130143823 | Compositions and methods of inhibiting apoptosis - A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFNγR2. | 2013-06-06 |
| 20130143824 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS - The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same. | 2013-06-06 |
| 20130143825 | COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF TOXIC TRANSCRIPTS - Compounds to be used in the treatment of diseases based on the expression of toxic transcripts. The present invention relates to peptide molecules, specifically hexapeptides, designed for the prevention and/or treatment of diseases the etiology whereof is based on the presence of toxic transcripts that comprise CUG, CCUG, CGG, CAG and AAG repeats, preferably: DM1 SCA8, DM2, FXTAS, HD and FA. | 2013-06-06 |
| 20130143826 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE - The present invention discloses chemical synthesis, anti-tumor and anti-metastatic effects of a dual functional conjugate as shown by formula I. Specifically, paclitaxel or docetaxol is linked with muramyl dipeptide derivative to form a conjugate, thus dual anti-tumor and anti-metastatic effects are achieved by combination of chemotherapy and immunotherapy. The present invention also discloses that paclitaxel or docetaxol and muramyl dipeptide derivative conjugate is synthesized by combination of solid-phase and solution-phase synthesis, and said conjugate can be used in manufacture of anti-tumor medicaments as proved by reliable bioassays. | 2013-06-06 |
| 20130143827 | TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF - A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided. | 2013-06-06 |
| 20130143828 | GLYCOLIPID FOR TREATMENT OF ISCHEMIA REPERFUSION INJURY - The invention relates to a high molecular weight glycolipid characterized by the presence of rhamnose which has anti-inflammatory activity, particularly in inflammation triggered by ischemia and reperfusion. A further aspect of the invention is a process for preparation of said glycolipid from Cyanobacteria. | 2013-06-06 |
| 20130143829 | Topical Combination Formulations of Macrocyclic Lactones with Synthetic Pyrethroids - The present invention provides pyrethroid/macrocyclic lactone-containing topical formulations that are effective against animal pests, including ecto- and endoparasites. The formulations may be used for combating parasites in or on birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite and/or pest infestation of birds and mammals. | 2013-06-06 |
| 20130143830 | AGENTS FOR COMBATING AND REDUCING THE IRRITATING ACTION OF SURFACTANTS IN COMPOSITIONS TO BE APPLIED TO THE SKIN FOR CARE OR CLEANSING OF THE FACE AND BODY - The present invention relates to the use of an agent to combat and reduce the irritating action of primary surfactants in compositions to be applied to the skin for care or cleansing of the face and body, characterized in that said agent is chosen from one or more salts of glycyrrhizic acid, such as monoammonium glycyrrhizinate (MAG) and dipotassium glycyrrhizinate (DPG). | 2013-06-06 |
| 20130143831 | TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING FLURBIPROFEN - The invention provides topical pharmaceutical compositions comprising flurbiprofen, or a pharmaceutically acceptable derivative thereof, in combination with a solubilising system which comprises at least one glycol ether and at least one glycol ester. These are suitable for treating any condition associated with pain, inflammation and/or stiffness, for example sub-dermal pain in the joints or soft tissue. | 2013-06-06 |
| 20130143832 | COMPOSITION FOR PREVENTING/CONTROLLING HARMFUL ARTHROPODS AND METHOD FOR PREVENTING/CONTROLLING HARMFUL ARTHROPODS - A harmful arthropod control composition comprising flonicamid, one or more insect growth regulator compounds selected from Group (A), and one or more sheath blight disease control compounds selected from Group (B):
| 2013-06-06 |
| 20130143833 | TRANSPLANTS - The present invention relates to a method of reducing injury to cells, a tissue or organ to be explanted from a body and upon implantation into a body by administering a composition to the cell, tissue or organ, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. The invention also provides a composition for reducing injury to vasculature ex vivo including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) an antiarrhythmic agent. | 2013-06-06 |
| 20130143834 | Cancer Treatment Method - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. | 2013-06-06 |
| 20130143835 | HCV Polymerase Inhibitors - The invention provides compounds of the formula: | 2013-06-06 |
| 20130143836 | PHARMACEUTICAL COMPOSITION FOR TREATING COAGULATION DISORDER HEMORRHAGE AND METHOD USING THE SAME - Pharmaceutical composition for treating hemorrhage caused by blood clotting disorder and use thereof. The pharmaceutical composition comprises (per unit): L-ornithine 0.5-8 g, aspartic acid 1-5 g, arginine 3-10 g and vitamin B6 3-10 g. The pharmaceutical composition can treat hemorrhage caused by blood clotting disorder effectively and is very appropriate for treating patient at stake. | 2013-06-06 |
| 20130143837 | INHIBITION OF TNF-ALPHA INDUCED ACTIVATION OF NFKB BY PENTOSAN POLYSULFATE - Oral pentosan polysulfate (PPS) compositions treat diseases such as diabetes, inflammation, atherosclerosis. The compositions are also effective in reducing matrix metalloproteinases (MMPs). | 2013-06-06 |
| 20130143838 | COMPLEX OBTAINED FROM HYALURONIC ACID OR A SALT THEREOF AND CHONDROITIN SULPHATE MIXTURES - The present invention relates to a novel complex, obtainable by mixing hyaluronic acid or a salt thereof and chondroitin sulphate or a salt thereof, and forming an aqueous solution of said mixture, which is further subjected to a drying process. The invention also relates to various compositions and formulations comprising the complex of the invention, process for obtaining said complex and uses thereof. | 2013-06-06 |
| 20130143839 | CYSTITIS TREATMENT WITH HIGH DOSE CHONDROITIN SULFATE - Interstitial cystitis and related GAG-deficient conditions of the bladder and urinary tract are treated by instillation of high dose chondroitin sulfate, such as 400 mg/20 mL. The higher dose of chondroitin is effective for the rapid reduction of symptoms, particularly in patients with severe and otherwise recalcitrant cystitis. | 2013-06-06 |
| 20130143840 | HEPARAN SULFATE REPLACEMENT THERAPY - The present invention relates to a method for inhibiting oxidative damage of islet beta cells in vivo in a subject by administering to the subject a therapeutically effective amount of heparan sulfate capable of protecting islet beta cells from reactive oxygen species or in vitro by exposing isolated islet beta cells, prior to transplantation, to a concentration of heparan sulfate that protects them from reactive oxygen species. | 2013-06-06 |
| 20130143841 | BENZOHETEROCYCLIC ANTI-BACTERIAL AGENTS - Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria. | 2013-06-06 |
| 20130143842 | STABLE AQUEOUS COMPOSITIONS COMPRISING BIOACTIVE CREATINE SPECIES - Compositions containing one or more bioactive forms of creatine, which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creatinol O-phosphate species to a mammalian subject, either chronically or acutely. | 2013-06-06 |
| 20130143843 | ARYL DIHYDROPYRIDINONE AND PIPERIDINONE MGAT2 INHIBITORS - The present invention provides compounds of Formula (I): | 2013-06-06 |
| 20130143844 | ECTOPARASITICIDE-CONTAINING PREPARATION FOR SPONTANEOUS EMULSION FORMATION - An emulsion concentrate for spontaneous emulsion preparation is described, comprising at least one ectoparasiticidal active ingredient. Moreover, a process for the preparation of a corresponding emulsion concentrate, and also its use for producing emulsions are described. An emulsion which is obtained starting from the emulsion concentrate, and also its use, are also described. | 2013-06-06 |
| 20130143845 | VITAMIN D COMPOUNDS AND METHODS FOR ENHANCING MUSCLE STRENGTH, AND PREVENTION AND TREATMENT OF DISEASE IN HUMAN BEINGS - Compositions and methods for enhancing muscular strength through the development of fast twitch skeletal muscle fibers comprising the steps of administering therapeutically effective amounts of Vitamin D, folic acid, calcium carbonate and potassium gluconate compounds to a subject, and the treatment and prevention of disease in human beings. | 2013-06-06 |
| 20130143846 | POLYMORPHIC FORM OF A CALCIMIMETIC COMPOUND - The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C | 2013-06-06 |
| 20130143847 | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS - The present disclosure relates generally to methods and compositions for treating symptoms of Parkinson's disease and/or other movement disorders. More particularly, the present disclosure describes a method for treating symptoms of Parkinson's disease and related disorders by administering a composition comprising one or more of the following active agents; estradiol, estriol, testosterone, and 19-nortestosterone. In addition, the compositions of the present invention can be used for enhancing or optimizing the effectiveness of neural stimulation in treating the symptoms of movement disorders such as Parkinson's disease. | 2013-06-06 |
| 20130143848 | USE OF MEGESTROL ACETATE FOR IMPROVING HEART FUNCTION AND THE TREATMENT OF HEART INSUFFICIENCY - The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace®; MA) in patients with heart insufficiency and after a myocardial infarction. | 2013-06-06 |
| 20130143849 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES - Disclosed herein are novel methods of treating respiratory diseases, and in particular the treatment of asthmatic children. | 2013-06-06 |
| 20130143850 | METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING - The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing. | 2013-06-06 |
| 20130143851 | Testosterone Solutions for the Treatment of Testosterone Deficiency - Solutions of testosterone for oromucosal administration providing an increase in serum testosterone levels in subjects deficient in endogenous testosterone levels, and therapeutic methods for providing an increase in serum testosterone levels and methods for treating a disease or a symptom associated with deficient endogenous levels of testosterone. | 2013-06-06 |
| 20130143852 | INFLAMMATORY DISEASE MODEL AND METHOD OF TREATMENT - Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as anti-inflammatory diets and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing reduction in the required anti-inflammatory drug maintenance dose. | 2013-06-06 |
| 20130143853 | ORAL SUSPENSION OF PREDNISOLONE ACETATE - The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation. | 2013-06-06 |
| 20130143854 | NUCLEAR SULFATED OXYSTEROL, POTENT REGULATOR OF LIPID HOMEOSTASIS, FOR THERAPY OF HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDES, FATTY LIVER DISEASES, AND ATHEROSCLEROSIS - The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear cholesterol metabolite that decreases lipid biosynthesis and increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol and/or triglycerides, and to prevent or treat lipid accumulation-associated inflammation and conditions associated with such inflammation. Methods which involve the use of this sulfated oxysterol to treat conditions associated with high cholesterol and/or high triglycerides and/or inflammation (e.g. hypercholesterolemia, hypertriglyceridemia, non-alcoholic fatty liver diseases, atherosclerosis, etc.) are also provided. | 2013-06-06 |
| 20130143855 | METHOD TO ALLEVIATE DIABETIC END STAGE RENAL DISEASE - A method of alleviating end-stage renal disease (ESRD), comprising administering an effective amount of a gel-danamycin derivative. | 2013-06-06 |
| 20130143856 | NOVEL ANTIBIOTIC COMPOSITION COMPRISING FLUFENAMIC ACID AS AN ACTIVE INGREDIENT - The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art. | 2013-06-06 |
| 20130143857 | PHARMACEUTICAL COMPOSITIONS OF CEFDITOREN PIVOXIL - The present invention relates to a pharmaceutical composition comprising Cefditoren pivoxil, water soluble high molecular weight substance and one or more pharmaceutically acceptable excipient wherein weight ratio of high molecular weight substance to Cefditoren pivoxil is greater than 1:4 and a process for preparation thereof. | 2013-06-06 |
| 20130143858 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS - The invention relates to compounds according to Formula I: | 2013-06-06 |
| 20130143859 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS - Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. | 2013-06-06 |
| 20130143860 | GUANIDINE COMPOUND | 2013-06-06 |
| 20130143861 | METHODS FOR TREATING ATRIAL FIBRILLATION - The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling. In some methods of the invention, budiodarone is administered 400 mg BID or more preferably 600 mg BID. | 2013-06-06 |
| 20130143862 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE - Provided are compounds of Formula I: | 2013-06-06 |
| 20130143863 | NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 2013-06-06 |
| 20130143864 | (6,7-DIHYDRO-2-NITRO-5H-IMIDAZOL[2,1-B][1,3]OXAZIN-6YL) AMIDE COMPOUNDS, PREPARATION METHODS AND USES THEREOF - (6,7-Dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)amide compounds of formula (I), and their pharmaceutically acceptable salts, preparation methods and pharmaceutical compositions thereof are disclosed, wherein m and R are defined as in the description. The uses of the compounds in preparing medicaments for treating infectious diseases caused by | 2013-06-06 |
| 20130143865 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. | 2013-06-06 |
| 20130143866 | ANTICANCER COMBINATION TREATMENTS - Compositions of matter including γ-tocotrienol and SU11274 are disclosed herein. A variety of Met kinase inhibitors may be used in conjunction with tocotrienols in the treatment or prevention of cancer. Combinations of γ-tocotrienol and SU11274 inhibit the cell growth of +SA mammary tumor cells. | 2013-06-06 |
| 20130143867 | ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME - Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs. | 2013-06-06 |
| 20130143868 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS - The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD). | 2013-06-06 |
| 20130143869 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE - Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity. | 2013-06-06 |
| 20130143870 | NOVEL COMPOUNDS - This invention relates to compounds of formula I | 2013-06-06 |
| 20130143871 | 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS - Aminoquinazolinyl compounds of formula (I) are described, which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing. | 2013-06-06 |
| 20130143872 | INJECTABLE FORMULATION OF A REVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT CANCER - This invention relates to a composition formulated into a parenteral or injectable dosage form for the treatment of cancer, more particularly, this invention relates to a composition formulated into a parenteral dosage form suitable for administration in and around cancerous tissue, the composition including: a pharmaceutically acceptable solvent including from 20% to 100% ethanol (V/V); and a reverse transcriptase inhibitor exhibiting an anti-cancer effect, dissolved in the solvent. | 2013-06-06 |
| 20130143873 | Diazoxide For Use In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) - The invention relates to the diazoxide or a pharmaceutically acceptable salt thereof for use as a medicament at low doses to treat amyotrophic lateral sclerosis. | 2013-06-06 |
| 20130143874 | FUSED RING PYRIDINE COMPOUND - [Problem] To provide a compound useful as a novel agent which is excellent in preventing and/or treating cannabinoid receptor type 2-related diseases, based on agonist action on a cannabinoid receptor type 2 | 2013-06-06 |
| 20130143875 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2013-06-06 |
| 20130143876 | New piperidine derivatives, pharmaceutical compositions and uses thereof - The invention relates to new piperidine derivatives of the formula I | 2013-06-06 |
| 20130143877 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND - A composition which comprises substance represented by Formula (I), | 2013-06-06 |
| 20130143878 | SUBSTITUTED DIBENZONAPHTHYRIDINES, PHARMACEUTICAL USES THEREOF AND PROCESSES THERFOR - The invention described herein pertains to substituted dibenzonaphthyridine compounds, pharmaceutical compositions, and formulations comprising the dibenzonaphthyridine compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer. | 2013-06-06 |
| 20130143879 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2013-06-06 |
| 20130143880 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 - The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR | 2013-06-06 |
| 20130143881 | Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam- ide - This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient. | 2013-06-06 |
| 20130143882 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Compounds having the structure which are selective inhibitors of P13K (phosphatidylinositol 3-kinase-delta), for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions. | 2013-06-06 |
| 20130143883 | MODULATORS FOR AMYLOID BETA - The invention relates to compounds of formula | 2013-06-06 |
| 20130143884 | 4-[2-[ [5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL] MORPHOLINE SALTS - The present invention relates to 4-[-2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts, specifically to the hydrochloride, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor associated diseases. | 2013-06-06 |
| 20130143885 | CHEMICAL INDUCERS OF NEUROGENESIS - The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy. | 2013-06-06 |
| 20130143886 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS - The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 2013-06-06 |
| 20130143887 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION - Novel compound having the following formula: | 2013-06-06 |
| 20130143888 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS - Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof. | 2013-06-06 |
| 20130143889 | Heterocycles As Potassium Channel Modulators - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, seizure, retinal degeneration, hearing and vision loss, Alzheimer's disease, age-10 related memory loss, learning deficiencies, anxiety, neuronal degeneration and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions. | 2013-06-06 |
| 20130143890 | CO-CRYSTAL INTERMEDIATES OF ROSUVASTATIN AND METHODS OF USING SAME - Methods for the preparation of Rosuvastatin by co-crystals of Rosuvastatin or intermediates are provided. Also provided are co-crystals, pharmaceutical compositions which include such co-crystals and methods for treating conditions associated with hypercholesterolemia by administering such compositions. | 2013-06-06 |
| 20130143891 | Methods for Treating Methotrexate-Resistant Disorders with 10-Propargyl-10-Deazaaminopterin - The present invention relates to a method for treating a methotrexate-resistant disorder in an individual, wherein the method comprises administering to the individual an effective amount of 10-propargyl-10-deazaminopterin or its pharmaceutically acceptable salts. | 2013-06-06 |
| 20130143892 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The present invention relates to compounds of general formula I, | 2013-06-06 |
| 20130143893 | PIPERAZINE DERIVATIVES AND METHODS OF USE - The invention provides 2-carboxamide piperazine compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility. | 2013-06-06 |
| 20130143894 | ORAL SPRAY FORMULATIONS AD METHODS FOR ADMINISTRATION OF SILDENAFIL - The present disclosure is directed to chemically-stable and pharmaceutically-acceptable sildenafil oral spray formulations for the treatment of male erectile dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating male erectile dysfunction. | 2013-06-06 |
